Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.55 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in salivary acinar cells | 0.75 |
| chemistry Open Targets | compounds already reach it: glycopyrronium tosylate, isopropamide iodide, bethanechol chloride +69 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 255 | 0.85 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 12563
Earlier readings: 2026-10-27 0.54; 2026-10-26 0.54; 2026-10-25 0.54; 2026-10-24 0.54.
Sealed predictions
- CHRM3 in dopamine neurons, braak+0.82 (p 0.007) → +0.63 (p 0.068)receipt 0583
- CHRM3 in dopamine neurons, braak-0.26 (p 0.100) → +0.09 (p 0.577)receipt 0124
- CHRM3 in dopamine neurons, resilience+0.14 (p 0.580) → +0.21 (p 0.511)receipt 0125
Swarm cases
receipt 0583: CHRM3 in dopamine neurons, braak
- power
- full sample +0.74 (p 4.4e-4, n 18), 95% CI +0.42 to +0.90. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.78 (p 1.5e-4, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.78 (p 1.6e-4, n 18). not the mix.
- skeptic
- leave-one-out range +0.71 to +0.91, sign flips 0; without severely affected donors +0.74 (p 4.4e-4, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CHRM3 in dopamine neurons.
case closed: nothing better to follow up.
receipt 0125: CHRM3 in dopamine neurons, resilience
- power
- full sample +0.17 (p 0.377, n 55), 95% CI -0.10 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for age, sex and PMI: +0.19 (p 0.344, n 55). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.12 (p 0.542); controlling for it: +0.19 (p 0.333, n 55). could be the mix.
- skeptic
- leave-one-out range +0.11 to +0.28, sign flips 0; without severely affected donors +0.18 (p 0.374, n 46). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "differs in resilient donors (Lewy pathology, no parkinsonism)" for CHRM3 in dopamine neurons.
case closed: nothing better to follow up.
receipt 0124: CHRM3 in dopamine neurons, braak
- power
- full sample -0.09 (p 0.418, n 84), 95% CI -0.30 to +0.13. the interval sits on zero: probably nothing there.
- confounder
- adjusted for age, sex and PMI: -0.05 (p 0.621, n 84). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis -0.72 (p 1.8e-14); controlling for it: -0.04 (p 0.743, n 84). could be the mix.
- skeptic
- leave-one-out range -0.12 to -0.06, sign flips 0; without severely affected donors -0.08 (p 0.474, n 75). fragile.
- cell type
- strongest in glutamate neurons: +0.52 (p 3.2e-7, n 84) vs -0.09 in dopamine neurons. proposing glutamate neurons.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CHRM3 in dopamine neurons.
follow-up confirmed in ventral tegmental area.
follow-up CHRM3 · glutamate neurons · braak: ventral tegmental area +0.50 p 2.0e-6 (needs p < 0.0026)
Receipts
loading the receipts